Catabasis Pharmaceuticals upgraded by HC Wainwright & Co. with a new price target
$CATB
Major Pharmaceuticals
Health Care
HC Wainwright & Co. upgraded Catabasis Pharmaceuticals from Neutral to Buy and set a new price target of $13.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/2/2021 | $16.00 | Outperform | Wedbush |
| 8/25/2021 | $13.00 | Neutral → Buy | HC Wainwright & Co. |
-- Astria Reflects Company's Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin Trading Under New Ticker Symbol ATXS on September 9 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. ("Astria" or the "Company"). The name Astria originates from the Greek word for star, reflecting the Company's commitment to having patients serve as guiding stars. Astria's mission is to bring hope with life-changing therapies to patients and famili
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. "We are focused on advancing the development of our lead program, QLS-215, as a differentiated and potentially the most patient-friendly treatment option for the chronic treatment of patients with hereditary angioedema to prevent attacks," said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. "We anticipate that our first clinical trial with QLS-215 could demonstrate clinical proof of concept of its differentiated profile and long antibody half-life. Initial results from this trial are anticipated
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET. The session entitled "HAE There- Development Landscape in Hereditary Angioedema (HAE)" will include an overview of the HAE treatment landscape, information about Catabasis's lead program QLS-215, and a Q&A session. A webcast of the presentation will be available at the following link: https://wsw.com/webcast/wedbush39/panel11/2571740, and will also be available in the investors section of the Company's
SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
Wedbush initiated coverage of Catabasis Pharmaceuticals with a rating of Outperform and set a new price target of $16.00
HC Wainwright & Co. upgraded Catabasis Pharmaceuticals from Neutral to Buy and set a new price target of $13.00
Ladenburg Thalmann initiated coverage of Catabasis Pharmaceuticals with a rating of Buy and set a new price target of $6.00
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. "We are focused on advancing the development of our lead program, QLS-215, as a differentiated and potentially the most patient-friendly treatment option for the chronic treatment of patients with hereditary angioedema to prevent attacks," said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. "We anticipate that our first clinical trial with QLS-215 could demonstrate clinical proof of concept of its differentiated profile and long antibody half-life. Initial results from this trial are anticipated
8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
8-K - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
S-8 - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)